ArticleJournal of virology2025
A short intrinsically disordered domain of MCPyV ALTO regulates TBK1 signaling during MCPyV infection.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biological Activity of Stilbenoids Against Fungal, Parasitic, and Viral Pathogens.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Merkel cell polyomavirus (MCPyV) is an oncogenic human polyomavirus that latently infects most adults. Although the causative link between MCPyV and Merkel cell carcinoma is well established, the molecular mechanisms that govern viral latency and prevent oncogenic progression remain poorly understood. We previously reported that the MCPyV early protein ALTO is a key modulator of the STING-TBK1 signaling axis, enabling the virus to co-opt innate immune pathways to suppress excessive viral replication and promote latency over transformation. In this study, we expand on this model by identifying a short, essential domain within ALTO that is required for TBK1 activation. This domain, which we term LIT (Lost in Tau), is necessary for ALTO-TBK1 interaction but dispensable for ALTO trafficking and its interactions with STING or Src. When expressed alone, the LIT domain functions as a dominant negative inhibitor of wild-type ALTO, competitively blocking TBK1 activation through a novel TBK1 interaction domain. Deletion of the LIT domain from ALTO not only abolishes TBK1 interaction and downstream phosphorylation but also eliminates TBK1-mediated suppression of MCPyV replication during early infection of human dermal fibroblasts. These findings provide mechanistic insight into how ALTO promotes viral persistence and immune evasion. More broadly, they highlight the functional importance of intrinsically disordered regions in modulating host-virus interactions and suggest that MCPyV latency is actively maintained through a finely tuned balance of pro- and anti-viral signaling. Identification of domains such as LIT provides new insight into TBK1 regulation and informs future strategies to study viral persistence.IMPORTANCEMerkel cell polyomavirus causes lifelong, latent infections in the skin of most people. When this latency is perturbed, the virus can give rise to Merkel cell carcinoma (MCC), an aggressive and difficult-to-treat skin cancer. Efforts to prevent this cancer depend on understanding what controls viral latency and persistence. We previously reported that MCPyV stimulates the host's STING-TBK1 signaling axis to limit its own replication. In this work, we identify and characterize a short amino acid motif within the ALTO protein's intrinsically disordered region that is required for this immune-stimulating activity. This region appears to be critical for helping the virus maintain latency by fine-tuning the host's response. Our findings provide new insight into how MCPyV may regulate early infection dynamics and suggest that identifying functional domains such as LIT could help guide future approaches to study viral persistence and its contribution to MCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.